Hey there,
It’s me again—your go-to person over here at the liposomal ingredients side of things, and I get it, when someone says “liposomes,” most folks first think of skincare or oral supplements, right? But lately, I’ve been fielding more and more questions from folks in the pharma, inhaler med, and respiratory device spaces: Can liposomal ingredients actually work in inhalers? Like, can those little phospholipid bubbles we source and craft make the jump from creams or capsules to something you breathe into your lungs? Liposomal Ingredients
If you’re here because you’re testing new inhaler formulations, dealing with sticky old APIs that just don’t deliver like they should, or even trying to cut down on side effects from harsh respiratory meds, let’s break this down—no stuffy lab jargon, just the real scoop we’ve picked up from working with this stuff day in and day out.
First, quick refresh on what liposomes are, because it’s key to why they work (or why some people wonder if they even can work here). Simply put, liposomes are tiny, spherical bubbles made of the same phospholipids that make up human cell membranes. That’s why they’re so biocompatible—your body doesn’t see ’em as some foreign invader to attack, which is a huge plus for anything touching your lungs, a super sensitive area. For the last 20+ years, we’ve supplied liposomal ingredients to all kinds of brands: skincare lines using them to boost absorption, supplement makers for fat-soluble vitamins like D or curcumin, and now more and more for respiratory formulations. But inhalers are a different beast, so there’s a lot to unpack here.
Let’s start with the big “why would anyone even put liposomes in an inhaler?” question, because the old-school inhaler stuff isn’t perfect. If you’ve used a rescue albuterol inhaler, you know part of the mist just floats away or gets stuck in your throat (that’s why sometimes your throat feels weird after) instead of actually landing on your lung tissue where it needs to go. Or for maintenance inhalers, some APIs are super harsh—they can irritate the airways, cause coughing, or even end up in your bloodstream causing systemic side effects that people deal with daily. Liposomes solve both of these problems, actually.
See, when you encapsulate an API (that active drug ingredient) inside a liposome, the little bubble acts like a delivery truck. It shrinks the API down to tiny, uniform particles that are way more likely to get deep into your alveoli—those tiny air sacs in the lungs where absorption matters most—instead of coating the back of your throat. Plus, because the liposome protects the API from being broken down too fast, you don’t need as high a dose, which cuts down on those side effects. That’s a win-win, right?
But wait—here’s the catch that’s stopped a lot of people from pulling the trigger: Liposomes are watery, right? Traditional metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) run on propellants or dry powder blends, and a lot of older liposomal formulations break down when you try to turn ’em into an inhaler—they clump, get too big, or the phospholipids separate from the API. For years, that was the hold-up, and we saw so many brands test it once, get frustrated, and move on. But here’s the thing: we’ve spent years tweaking our liposomal ingredients to fix exactly that. We don’t just sell generic phospholipid blends anymore—we craft liposomes that are tailor-made for inhalation formulations, with particle sizes that stay stable in MDI propellants or dry powder matrices, even at high shear forces during manufacturing.
Let’s get specific about the formulation stuff, because that’s where most of the confusion is. When you make liposomes for oral use, they’re usually small, soft, and aqueous, which works for drinking or putting in a capsule. But for inhalers, you need the liposomes to hold their structure through the entire process: mixing with propellant, being aerosolized through the inhaler mouthpiece, and floating long enough to reach the lower lungs. Our liposomal ingredients are engineered with a precise mix of saturated and unsaturated phospholipids, plus a tiny amount of cholesterol (not the bad kind—just a lipid that stabilizes the bilayer) that keeps the bubble intact when it’s mixed with the harsh chemicals in MDI propellants, or when it’s lyophilized (freeze-dried) for DPIs. We test every batch to make sure the particle size distribution is within that sweet spot: 1 to 5 microns, the exact range that’s proven to deposit deep in the lungs without getting stuck in the mouth or throat.
I know some of you are thinking, “Wait, have there actually been any successful inhalers using liposomes? Or is this just a cool lab trick?” Let’s talk real-world examples, because that’s what matters. A few years back, there was a nebulized liposomal amikacin for chronic lung infections in cystic fibrosis patients— that got FDA approval a while back, right? Nebulizers are a bit different from MDIs or DPIs, but it’s proof the concept works. More recently, we’ve worked with a couple of pharma R&D teams that are testing liposomal budesonide for asthma maintenance—early data showed 30% higher lung deposition than standard dry powder budesonide, and way less throat irritation because the dose is lower. Another team is working on liposomal fentanyl for breakthrough cancer pain in patients who can’t take oral meds, and the inhalation route using our liposomes is making a lot of headway.
But let’s be honest—this isn’t a one-size-fits-all thing, and there are hurdles we still have to work through, which is why our role as a liposomal ingredient supplier isn’t just shipping product, it’s problem-solving with you. For example, some APIs are super hydrophobic—they don’t mix with water, so encapsulating them in a liposome takes a little extra tweaking. We don’t just send you a bag of phospholipids and say “good luck”; our in-house formulation team works with you to adjust the lipid ratio, the encapsulation method, even the pH of the solution to make sure your API is locked safely inside the liposome, stable through manufacturing, and effective once it’s in the lungs.
Another big one: regulatory stuff. A lot of inhaler developers are worried about meeting FDA or EMA guidelines, especially for particle size stability and purity. Our liposomal ingredients are all GMP-made, batch-tested for residual solvents, endotoxins, and that uniform particle size we talked about, so you don’t have to do all the extra work to hit compliance. We’ve got a whole library of data packages you can use for regulatory submissions, too—no more starting from scratch.
I’ve heard the skepticism too, though. Like, why didn’t this catch on faster? Part of it was the old formulations that couldn’t handle inhaler processing, and part of it was that most liposomal suppliers only focused on skincare or oral supplements, so they didn’t understand the unique needs of inhalation. That’s where we’re different—we specialize in liposomal ingredients for drug delivery across all routes, not just one, so we get both the science of liposomes and the specific demands of inhaler manufacturing. For example, when a client comes to us with an API that’s causing coughing in their current inhaler, we can tell them how adjusting the liposome’s bilayer rigidity can slow down API release so it’s gentler on the airways, without losing efficacy. It’s not rocket science, but it’s the kind of tailored support you don’t get from a generic supplier.
Let’s also clear up a myth: liposomes in inhalers don’t add any extra side effects beyond the API, and since the dose is lower, side effects are often better. Because the phospholipids are naturally occurring, your body breaks them down into fatty acids and glycerol, just like it does from the food you eat—there’s no weird buildup or toxic stuff. We’ve tested our liposomal ingredients in human cell cultures and animal models, and the biocompatibility scores are through the roof, way better than some synthetic excipients used in traditional inhalers.
If you’re still on the fence, think about what you’re trying to solve. Are you struggling with low lung deposition rates that mean your patients aren’t getting enough medication? Are side effects like throat thrush or systemic jitters turning people off from your inhaler? Are you dealing with APIs that are unstable in traditional formulations? Liposomal inhaler tech checks all those boxes, and it’s only getting better as we refine our ingredients.
At the end of the day, this is what gets us excited: helping respiratory med teams make products that actually work for people who need them, not just checking boxes on a formulation sheet. We’ve got a whole line of inhalation-grade liposomal ingredients ready to go, and our team can work with you to customize anything—from particle size to lipid composition—to fit your specific API and inhaler type (MID, DPI, nebulizer).
If you’re ready to stop messing with inhaler formulations that don’t deliver, or just want to pick our brains about how liposomes could work for your product, reach out and connect for a supply discussion. We don’t do stuffy sales pitches—we sit down with you, break down the science that matters, and make sure you have the ingredients and support to get your inhaler to market faster.
Botanical Extract Ingredients References:
- Allen TM, Cullis PR. Liposomal drug delivery systems: past, present, and future. Adv Drug Deliv Rev. 2013;65(1):36-48.
- Elhissi A, Zhang Y, D’Emanuele A. Liposomal aerosols for respiratory drug delivery. J Control Release. 2010;145(2):136-145.
- Geller DE, et al. Inhaled liposomal amikacin for treatment of chronic pulmonary Mycobacterium avium complex disease. Am J Respir Crit Care Med. 2018;197(10):1332-1340.
- Traini D, Young PM. Liposomes for pulmonary drug delivery: a review. J Pharm Sci. 2008;97(1):296-309.
Natural Field Co., Ltd.
Natural Field Co., Ltd. is one of the most professional liposomal ingredients manufacturers and suppliers in China, featured by quality products and good price. Please feel free to buy bulk CE approved liposomal ingredients from our factory. For more discount information, contact us now.
Address: Room 505, Building B, Rongcheng Yungu, No. 57 Keji 3rd Road, Zhangba Subdistrict, High-tech Zone, Xi’an, Shaanxi, China
E-mail: info@natural-field.com
WebSite: https://www.naturalfieldtech.com/
